Tezspire Hits Both Co-Primary Endpoints in Phase III EoE Trial, Sustained Through Week 52
AZN sits 17% above its 52-week low of $141.772.
Summary
AstraZeneca and Amgen's Tezspire met both co-primary endpoints and all key secondary endpoints in the Phase III CROSSING trial for eosinophilic esophagitis, with efficacy sustained through week 52. The results support a potential third indication for the drug.
Key Events · Product Development and Regulatory · AZN
-
CROSSING Trial Meets Both Co-Primary Endpoints
Tezspire achieved statistically significant and clinically meaningful improvements in histologic remission and dysphagia frequency/severity versus placebo at week 24 in 368 patients with eosinophilic esophagitis.
-
Efficacy Sustained Through Week 52
Benefits were maintained through week 52 across both doses tested, with all key secondary endpoints also met, including endoscopic disease features and histologic severity.
-
Third Epithelial-Driven Indication
Tezspire has now shown efficacy in a third epithelial-driven inflammatory disease, following approvals in severe asthma and chronic rhinosinusitis with nasal polyps, supporting broad pipeline potential.
-
Commercial Opportunity in EoE
EoE affects over 470,000 people in the US with prevalence increasing five-fold since 2009; nearly half of patients do not achieve adequate control on current first-line therapies.
Analysis · AZN · Life Sciences
Tezspire delivered statistically significant and clinically meaningful improvements across both co-primary endpoints—histologic remission and dysphagia severity—as well as all key secondary endpoints at week 24, with benefits sustained through week 52. This marks the third epithelial-driven inflammatory disease in which Tezspire has shown efficacy, supporting a broad label expansion opportunity beyond its current severe asthma and CRSwNP approvals. EoE affects over 470,000 people in the US, and nearly half of patients do not achieve adequate control on first-line therapy, representing a meaningful commercial opportunity for AstraZeneca and Amgen's shared franchise.
How filings like this one have moved
In the 30 days to Sep 7, 2026, 36.5% of the 1933 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AZN was trading at $165.36 on NYSE in the Life Sciences sector, with a market capitalization of approximately $257.9B. The 52-week trading range was $141.77 to $212.71. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.